Table 3.
Relatedness of death at 12–33 months to bleeding, cancer, and trauma according to blinded adjudication
| Continued thienopyridine (n = 5862), n (%) | Placebo (n = 5786), n (%) | Difference | P-value | |
|---|---|---|---|---|
| Relatedness to bleeding, cancer, and/or trauma | ||||
| All bleeding-related death | 18 (0.3) | 12 (0.2) | +6 (0.1) | 0.36 |
| Bleeding-related death without cancera or trauma | 7 (0.1) | 7 (0.1) | +0 (0.0) | |
| Bleeding-related death with cancer | 3 (0.1) | 0 (0.0) | +3 (0.1) | |
| Bleeding-related death with trauma | 8 (0.1) | 5 (0.1) | +3 (0.1) | |
| All cancer-related death | 34 (0.6) | 17 (0.3) | +17 (0.3) | 0.02 |
| Cancer-related death without bleedingb | 31 (0.5) | 17 (0.3) | +14 (0.2) | |
| All trauma-related deathc | 10 (0.2) | 5 (0.1) | +5 (0.1) | 0.30 |
| Trauma-related death without bleedingb | 2 (0.0) | 0 (0.0) | +2 (0.0) | |
Event rates are expressed as absolute percentages.
aWithout possible, probable, or definite cancer-related death.
bWithout possible, probably, or definite bleeding-related death.
cTrauma included five motor vehicle accidents, three suicides/gun shots, four major trauma/crush injuries, two falls/head trauma, and one thigh haematoma without documented history of trauma.